The FDA placed Aardvark Therapeutics’ program for Prader-Willi syndrome under full clinical hold, stopping all tests of its small-molecule candidate ARD-101. The hold follows a prior trial pause after potential cardiovascular problems appeared in a healthy-volunteer study using higher doses than those planned elsewhere. Aardvark said it will unblind dosing assignments to support regulator review.